{"id":"valsartan-aliskiren","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and other tissues, causing vasodilation and reduced aldosterone secretion. Aliskiren is a direct renin inhibitor that blocks the first step of the renin-angiotensin cascade, preventing the conversion of angiotensinogen to angiotensin I. Together, they provide complementary inhibition of this system for enhanced blood pressure reduction.","oneSentence":"This combination blocks two pathways in the renin-angiotensin-aldosterone system: valsartan blocks angiotensin II receptors while aliskiren inhibits renin, reducing blood pressure through dual inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:06.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00219102","phase":"PHASE3","title":"A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Hypertension, Diabetes","enrollment":336},{"nctId":"NCT01252238","phase":"NA","title":"Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2010-06","conditions":"Insulin Sensitivity, Aortic Compliance, Diastolic Function","enrollment":24},{"nctId":"NCT01318395","phase":"PHASE3","title":"Aliskiren on Retinal Vasculature Treatment Study","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2010-05","conditions":"Arterial Hypertension","enrollment":56},{"nctId":"NCT00219180","phase":"PHASE3","title":"Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Hypertension","enrollment":1797},{"nctId":"NCT00219193","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Hypertension","enrollment":641},{"nctId":"NCT00939588","phase":"PHASE2","title":"Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Hypertension","enrollment":88},{"nctId":"NCT01129557","phase":"PHASE4","title":"Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease","status":"TERMINATED","sponsor":"Columbia University","startDate":"2009-09","conditions":"Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis","enrollment":46},{"nctId":"NCT00386607","phase":"PHASE3","title":"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Hypertension","enrollment":601},{"nctId":"NCT01432106","phase":"PHASE1","title":"The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2011-02","conditions":"Hypertension, Metabolic Syndrome","enrollment":""},{"nctId":"NCT01368536","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Hypertension, Stage 2 Hypertension, Diabetes","enrollment":975},{"nctId":"NCT00927394","phase":"PHASE4","title":"Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-05","conditions":"Hypertension","enrollment":1143},{"nctId":"NCT00819767","phase":"PHASE2","title":"Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-02","conditions":"Hypertension","enrollment":68},{"nctId":"NCT00809926","phase":"PHASE4","title":"8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-01","conditions":"Stage 2 Hypertension","enrollment":451},{"nctId":"NCT00409578","phase":"PHASE2","title":"Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Post Acute Coronary Syndrome, Myocardial Ischemia","enrollment":1101},{"nctId":"NCT01095822","phase":"PHASE4","title":"Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics","status":"UNKNOWN","sponsor":"HeartDrug Research LLC","startDate":"2010-03","conditions":"Diabetes Mellitus","enrollment":50},{"nctId":"NCT00416728","phase":"PHASE1","title":"Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Healthy","enrollment":32},{"nctId":"NCT00416468","phase":"PHASE1","title":"Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Healthy","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":125,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Valsartan/aliskiren","genericName":"Valsartan/aliskiren","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination blocks two pathways in the renin-angiotensin-aldosterone system: valsartan blocks angiotensin II receptors while aliskiren inhibits renin, reducing blood pressure through dual inhibition. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}